• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

测量良性前列腺增生男性患者的疾病特异性健康状况。美国泌尿外科学会测量委员会。

Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association.

作者信息

Barry M J, Fowler F J, O'Leary M P, Bruskewitz R C, Holtgrewe H L, Mebust W K

机构信息

Medical Practices Evaluation Center, Massachusetts General Hospital, Boston 02114, USA.

出版信息

Med Care. 1995 Apr;33(4 Suppl):AS145-55.

PMID:7536866
Abstract

In preparation for an outcomes study of benign prostatic hyperplasia (BPH), two measures of disease-specific health status were developed to supplement a symptom score and overall health status measures. The symptom problem index (SPI) captures how troublesome patients find their urinary symptoms. The BPH impact index (BII) measures how much their urinary problems affect various domains of health. A prospective revalidation of the refined instruments (N = 108 BPH patients and 50 controls) documented that both indices had good internal consistency (Cronbach's alpha = 0.88 and 0.79, respectively) and test-retest (r = 0.88 for both) reliabilities, correlated strongly with symptom scores (r = 0.86 and 0.77), and discriminated between BPH and control subjects (receiver-operating characteristic areas = 0.87 and 0.85, respectively). These indices were nearly as responsive as symptom scores in 50 men actively treated for BPH, and much more responsive than a non-disease-specific General Health Index (GHI), a Mental Health Index (MHI), and an Activity Index (AI). Finally, these measures capture most of the health status significance of BPH symptoms. In linear regression models constructed to predict scores on the GHI, MHI, and AI, symptom scores added little explanatory power to the SPI and, particularly, to the BII. These measures help clarify how BPH affects overall health status and function. Such measures have an important role to play in studies of the outcomes of treatment for BPH, and probably for other conditions that interfere with health status and function.

摘要

为开展一项良性前列腺增生(BPH)的疗效研究,研发了两种疾病特异性健康状况测量方法,以补充症状评分和总体健康状况测量方法。症状问题指数(SPI)反映患者认为其泌尿系统症状的困扰程度。BPH影响指数(BII)衡量其泌尿系统问题对健康各个领域的影响程度。对优化后的工具进行的前瞻性再验证(108例BPH患者和50例对照)表明,这两个指数均具有良好的内部一致性(Cronbach's α分别为0.88和0.79)和重测信度(两者的r均为0.88),与症状评分密切相关(r分别为0.86和0.77),并且能够区分BPH患者和对照对象(受试者工作特征曲线下面积分别为0.87和0.85)。在50例接受积极治疗的BPH男性患者中,这些指数的反应性与症状评分几乎相同,并且比非疾病特异性的一般健康指数(GHI)、心理健康指数(MHI)和活动指数(AI)更具反应性。最后,这些测量方法涵盖了BPH症状在健康状况方面的大部分重要意义。在用于预测GHI、MHI和AI评分的线性回归模型中,症状评分对SPI,尤其是对BII的解释力增加很少。这些测量方法有助于阐明BPH如何影响总体健康状况和功能。此类测量方法在BPH治疗疗效研究以及可能在其他影响健康状况和功能的疾病研究中具有重要作用。

相似文献

1
Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association.测量良性前列腺增生男性患者的疾病特异性健康状况。美国泌尿外科学会测量委员会。
Med Care. 1995 Apr;33(4 Suppl):AS145-55.
2
Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.坦索罗辛对良性前列腺增生症患者总体及症状特异性生活质量的临床影响:采用国际前列腺症状评分和兰德医疗结局研究36项健康调查
Int J Urol. 2006 Sep;13(9):1202-6. doi: 10.1111/j.1442-2042.2006.01594.x.
3
Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting.在临床实践环境中,国际前列腺症状评分困扰问题与良性前列腺增生影响指数的相关性。
BJU Int. 2008 Jun;101(12):1531-5. doi: 10.1111/j.1464-410X.2008.07574.x. Epub 2008 Apr 28.
4
Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.全科医生对接受阿夫唑嗪治疗的临床良性前列腺增生男性患者的前瞻性研究:1年结果。
Urology. 1996 Nov;48(5):731-40. doi: 10.1016/S0090-4295(96)00302-0.
5
Prevalence and bothersomeness of lower urinary tract symptoms in benign prostatic hyperplasia and their impact on well-being.良性前列腺增生中下尿路症状的患病率、困扰程度及其对生活质量的影响。
J Urol. 2001 Aug;166(2):563-8.
6
Using the ICSOoL to measure the impact of lower urinary tract symptoms on quality of life: evidence from the ICS-'BPH' Study. International Continence Society--Benign Prostatic Hyperplasia.使用国际前列腺症状评分(ICSOoL)评估下尿路症状对生活质量的影响:来自国际尿控协会-良性前列腺增生症(ICS-‘BPH’)研究的证据。国际尿控协会-良性前列腺增生症
Br J Urol. 1997 Nov;80(5):712-21.
7
[Quality of life assessment of the male with benign prostate hypertrophy].[良性前列腺增生男性的生活质量评估]
Acta Med Croatica. 2007 Feb;61(1):49-55.
8
Change in urinary symptoms and quality of life in men with benign prostatic hyperplasia after transurethral resection of prostate.经尿道前列腺切除术后良性前列腺增生男性患者的尿路症状及生活质量变化
Nepal Med Coll J. 2007 Dec;9(4):255-8.
9
Prostatic central zone volume, lower urinary tract symptom severity and peak urinary flow rates in community dwelling men.社区居住男性的前列腺中央区体积、下尿路症状严重程度及最大尿流率
J Urol. 1999 Mar;161(3):831-4.
10
Diagnostic and predictive value of voiding diary data versus prostate volume, maximal free urinary flow rate, and Abrams-Griffiths number in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.排尿日记数据与前列腺体积、最大自由尿流率及艾布拉姆斯-格里菲思数对提示良性前列腺增生的下尿路症状男性的诊断和预测价值。
Urology. 2008 Mar;71(3):469-74. doi: 10.1016/j.urology.2007.11.033.

引用本文的文献

1
Electroacupuncture for lower urinary tract symptoms in men with benign prostatic hyperplasia: study protocol for a randomised controlled trial.电针对良性前列腺增生男性下尿路症状的影响:一项随机对照试验的研究方案。
BMJ Open. 2024 Jul 20;14(7):e080743. doi: 10.1136/bmjopen-2023-080743.
2
Prospective Trial of Water Vapor Thermal Therapy for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia in Subjects with a Large Prostate: 6- and 12-month Outcomes.水蒸气热疗法治疗前列腺体积较大的良性前列腺增生所致下尿路症状的前瞻性试验:6个月和12个月结果
Eur Urol Open Sci. 2023 Nov 8;58:64-72. doi: 10.1016/j.euros.2023.10.006. eCollection 2023 Dec.
3
Prostatic Artery Embolization as a Treatment Option for Symptomatic Benign Prostatic Hyperplasia: Results from the Prospective Follow-Up Study in Lithuania.
前列腺动脉栓塞术作为治疗症状性良性前列腺增生的一种选择:来自立陶宛前瞻性随访研究的结果。
Medicina (Kaunas). 2023 Oct 21;59(10):1871. doi: 10.3390/medicina59101871.
4
Comprehensive Analysis of Individual Anatomical Structures for Micturition Symptoms and Maximum Flow Rate in Men With Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms.良性前列腺增生/下尿路症状男性排尿症状和最大尿流率的个体解剖结构综合分析
Int Neurourol J. 2023 Jun;27(2):146-154. doi: 10.5213/inj.2346046.023. Epub 2023 Jun 30.
5
Simplified Chinese version of the international prostate symptom score and the benign prostatic hyperplasia impact index: cross-cultural adaptation, reliability, and validity for patients with benign prostatic hyperplasia.国际前列腺症状评分和良性前列腺增生影响指数的简体中文版:良性前列腺增生患者的跨文化调适、信度和效度
Prostate Int. 2022 Sep;10(3):162-168. doi: 10.1016/j.prnil.2022.04.001. Epub 2022 May 10.
6
Features of patients referring to the outpatient office due to benign prostatic hyperplasia: analysis of a national prospective cohort of 5815 cases.因良性前列腺增生而就诊于门诊的患者的特征:一项全国前瞻性队列研究 5815 例的分析。
Prostate Cancer Prostatic Dis. 2023 Dec;26(4):730-735. doi: 10.1038/s41391-022-00575-w. Epub 2022 Jul 22.
7
Prevalence of benign prostatic hyperplasia among the adult general population of five Middle Eastern Countries: Results of the SNAPSHOT programme.五个中东国家成年普通人群中良性前列腺增生的患病率:SNAPSHOT项目的结果。
Arab J Urol. 2022 Jan 23;20(1):14-23. doi: 10.1080/2090598X.2021.2010451. eCollection 2022.
8
Efficacy and Safety of the Hexanic Extract of vs. Watchful Waiting in Men with Moderate to Severe LUTS-BPH: Results of a Paired Matched Clinical Study.与等待观察相比,[具体药物名称]正己烷提取物治疗中重度下尿路症状伴良性前列腺增生男性患者的疗效与安全性:一项配对匹配临床研究的结果
J Clin Med. 2022 Feb 12;11(4):967. doi: 10.3390/jcm11040967.
9
Short-term efficacy and safety of second generation bipolar transurethral vaporization of the prostate (B-TUVP) for large benign prostate enlargement: Results from a retrospective feasibility study.第二代双极经尿道前列腺汽化术(B-TUVP)治疗大体积良性前列腺增生的短期疗效和安全性:一项回顾性可行性研究结果。
PLoS One. 2021 Dec 16;16(12):e0261586. doi: 10.1371/journal.pone.0261586. eCollection 2021.
10
Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients.锯叶棕果实的正己烷提取物与坦索罗辛治疗中重度 LUTS-BPH 患者的疗效和耐受性比较。
Sci Rep. 2021 Sep 29;11(1):19401. doi: 10.1038/s41598-021-98586-5.